宫颈癌患者血清中的CD44剪接变体

Serum CD44 splice variants in cervical cancer patients.

作者信息

Kainz C, Tempfer C, Winkler S, Sliutz G, Koelbl H, Reinthaller A

机构信息

Department of Gynaecology and Obstetrics, University of Vienna Medical School, Austria.

出版信息

Cancer Lett. 1995 Apr 14;90(2):231-4. doi: 10.1016/0304-3835(95)03708-5.

DOI:10.1016/0304-3835(95)03708-5

PMID:7537626

Abstract

Aberrant expression of the cell adhesion molecule CD44 has been detected in human tumours and has been shown to be associated with metastasis and poor prognosis in human malignancies. We evaluated serum levels of different soluble CD44 molecules (CD44 standard form and CD44 splice variants v5 and v6) in cervical cancer patients stage IB to IIIB. Two-hundred three serum samples were analysed. Serum levels of CD44st and CD44v5 showed no significant correlation with the presence or absence of cervical cancer. The splice variant CD44v6 showed a mean concentration of 227.3 +/- 90.9 (minimum 71.4, maximum 543.9) ng/ml when tumour was present and a mean concentration of 198.7 +/- 135.4 (minimum 67.2, maximum 696.3) ng/ml in cases of complete remission (P-value = 0.0001). However, in this preliminary study the sensitivity/specificity characteristic of CD44v6 was poor.

摘要

细胞黏附分子CD44的异常表达已在人类肿瘤中被检测到，并且已显示与人类恶性肿瘤的转移和不良预后相关。我们评估了IB至IIIB期宫颈癌患者血清中不同可溶性CD44分子（CD44标准型和CD44剪接变体v5和v6）的水平。分析了203份血清样本。CD44st和CD44v5的血清水平与宫颈癌的存在与否无显著相关性。当存在肿瘤时，剪接变体CD44v6的平均浓度为227.3±90.9（最小值71.4，最大值543.9）ng/ml，在完全缓解的病例中平均浓度为198.7±135.4（最小值67.2，最大值696.3）ng/ml（P值=0.0001）。然而，在这项初步研究中，CD44v6的敏感性/特异性特征较差。